Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Palvella Therapeutics Inc. | QTORIN rapamycin | Angiokeratomas | Phase 2 | Trial Planned | Topical | #N/A |
| Palvella Therapeutics Inc. | QTORIN - (TOIVA) | Cutaneous venous malformations (VMs) | Phase 2 | Data Released | topical | N/A |
| Panbela Therapeutics Inc. | SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE) | Pancreatic Ductal Adenocarcinoma (PDA) | Phase 2/3 | Ongoing | Intravenous | Oncology |
| Panbela Therapeutics Inc. | CPP-1X-T (Eflornithine tablets) - (TADPOL) | Type 1 diabetes | Phase 2 | Ongoing | Oral | Endocrinology |
| Panbela Therapeutics Inc. | CPP-1X-T (Eflornithine tablets) | Type 1 Diabetes | Phase 2 | Data Released | Oral | Endocrinology |
| PaxMedica Inc. | PAX-HAT-301 | Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (Stage 1 TBR HAT) | NDA Filing | Ongoing | Oral | Antiviral |
| PaxMedica Inc. | PAX-101 - (suramin) | Fragile X syndrome | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| PDS Biotechnology Corporation | PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002) | HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) | Phase 3 | Type Meeting | PDS0101 intradermal KEYTRUDA intravenous | Oncology |
